Actinogen Locks Database for Pivotal Alzheimer’s Trial; Results on Track for Mid-November
Actinogen Medical says it has formally achieved database lock in its pivotal XanaMIA trial of oral Xanamem and remains on track to report topline results in mid-November.
Story updates
12:55:11 PM UTC
SquawkNews
Actinogen Medical Limited achieved database lock for its pivotal XanaMIA Alzheimer’s trial and narrowed topline readout timing to mid-November, from November.Material DetailsContext by AI AnalystThis tightens timing on a known late-stage AD trial, moving the story from execution risk to imminent da…